QRK309: QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery

Project: Industrial Collaboration and DevelopmentClinical Trials with Industrial Collaboration

Project Details

Description

This is a randomized, double-blind, placebo-controlled, Phase 3 trial to evaluate QPI-1002 versus placebo for the prevention of Major Adverse Kidney Events in subjects at high risk for acute kidney injury following cardiac surgery. Subjects will be dosed with active drug or placebo after the completion of cardiovascular surgery
Statusfinished
Effective start/end date15.05.1931.12.21

UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This project contributes towards the following SDG(s):

  • SDG 3 - Good Health and Well-being

Research Areas and Centers

  • Research Area: Center for Population Medicine and Public Health (ZBV)

DFG Research Classification Scheme

  • 2.22-12 Cardiology, Angiology

Funding Institution

  • Industrial Collaboration

ASJC Subject Areas

  • Anesthesiology and Pain Medicine
  • Nephrology
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.